Department of Periodontology and Implant Dentistry, New York University, New York, New York.
Department of Preventive Medicine, Stony Brook University School of Medicine, Stony Brook, New York.
JAMA. 2013 Dec 18;310(23):2523-32. doi: 10.1001/jama.2013.282431.
Chronic periodontitis, a destructive inflammatory disorder of the supporting structures of the teeth, is prevalent in patients with diabetes. Limited evidence suggests that periodontal therapy may improve glycemic control.
To determine if nonsurgical periodontal treatment reduces levels of glycated hemoglobin (HbA1c) in persons with type 2 diabetes and moderate to advanced chronic periodontitis.
DESIGN, SETTING, AND PARTICIPANTS: The Diabetes and Periodontal Therapy Trial (DPTT), a 6-month, single-masked, multicenter, randomized clinical trial. Participants had type 2 diabetes, were taking stable doses of medications, had HbA1c levels between 7% and less than 9%, and untreated chronic periodontitis. Five hundred fourteen participants were enrolled between November 2009 and March 2012 from diabetes and dental clinics and communities affiliated with 5 academic medical centers.
The treatment group (n = 257) received scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months. The control group (n = 257) received no treatment for 6 months.
Difference in change in HbA1c level from baseline between groups at 6 months. Secondary outcomes included changes in probing pocket depths, clinical attachment loss, bleeding on probing, gingival index, fasting glucose level, and Homeostasis Model Assessment (HOMA2) score.
Enrollment was stopped early because of futility. At 6 months, mean HbA1c levels in the periodontal therapy group increased 0.17% (SD, 1.0), compared with 0.11% (SD, 1.0) in the control group, with no significant difference between groups based on a linear regression model adjusting for clinical site (mean difference, -0.05% [95% CI, -0.23% to 0.12%]; P = .55). Periodontal measures improved in the treatment group compared with the control group at 6 months, with adjusted between-group differences of 0.28 mm (95% CI, 0.18 to 0.37) for probing depth, 0.25 mm (95% CI, 0.14 to 0.36) for clinical attachment loss, 13.1% (95% CI, 8.1% to 18.1%) for bleeding on probing, and 0.27 (95% CI, 0.17 to 0.37) for gingival index (P < .001 for all).
Nonsurgical periodontal therapy did not improve glycemic control in patients with type 2 diabetes and moderate to advanced chronic periodontitis. These findings do not support the use of nonsurgical periodontal treatment in patients with diabetes for the purpose of lowering levels of HbA1c.
clinicaltrials.gov Identifier: NCT00997178.
重要性:慢性牙周炎是一种破坏性的牙齿支持组织炎症性疾病,在糖尿病患者中很常见。有限的证据表明,牙周治疗可能改善血糖控制。
目的:确定非手术性牙周治疗是否能降低 2 型糖尿病和中重度慢性牙周炎患者的糖化血红蛋白(HbA1c)水平。
设计、地点和参与者:为期 6 个月的、单盲、多中心、随机临床试验,即糖尿病和牙周治疗试验(DPTT)。参与者患有 2 型糖尿病,正在服用稳定剂量的药物,HbA1c 水平在 7%至低于 9%之间,且患有未经治疗的慢性牙周炎。2009 年 11 月至 2012 年 3 月,从糖尿病和牙科诊所以及 5 家学术医疗中心附属社区招募了 514 名参与者。
干预措施:治疗组(n=257)在基线时接受刮治和根面平整术加氯己定口腔冲洗,在第 3 个月和第 6 个月接受支持性牙周治疗。对照组(n=257)在 6 个月内未接受任何治疗。
主要结果和测量:6 个月时两组之间 HbA1c 水平从基线变化的差异。次要结局包括探测袋深度、临床附着丧失、探诊出血、牙龈指数、空腹血糖水平和稳态模型评估(HOMA2)评分的变化。
结果:由于无效,提前停止了入组。6 个月时,牙周治疗组的平均 HbA1c 水平升高 0.17%(标准差[SD],1.0),而对照组升高 0.11%(SD,1.0),两组之间无显著差异,基于调整临床地点的线性回归模型(平均差异,-0.05%[95%置信区间,-0.23%至 0.12%];P=0.55)。与对照组相比,治疗组的牙周措施在 6 个月时有所改善,调整后的组间差异分别为 0.28 毫米(95%置信区间,0.18 毫米至 0.37 毫米)的探诊深度、0.25 毫米(95%置信区间,0.14 毫米至 0.36 毫米)的临床附着丧失、13.1%(95%置信区间,8.1%至 18.1%)的探诊出血和 0.27(95%置信区间,0.17 毫米至 0.37 毫米)的牙龈指数(均 P<0.001)。
结论和相关性:非手术性牙周治疗并不能改善 2 型糖尿病和中重度慢性牙周炎患者的血糖控制。这些发现不支持在糖尿病患者中使用非手术性牙周治疗来降低 HbA1c 水平。
试验注册:clinicaltrials.gov 标识符:NCT00997178。